Hours after reporting its first quarterly earnings as a commercial entity following FDA approval of Kynamro (mipomersen) in January and subsequent launch of the antisense drug, Isis Pharmaceuticals Inc. turned its attention to other candidates in its pipeline. Read More
Researchers have identified a protein that can reverse cardiac hypertrophy, the thickening of the heart muscle that is one of the key features of diastolic heart failure. Read More
When is a drug compounder a manufacturer vs. a pharmacy? That's the question the Senate Health, Education, Labor and Pensions Committee grappled with Thursday as it closed in on a bill it can send to the Senate floor that would better regulate compounding pharmacies without opening a loophole around the drug approval process. Read More
Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million. Read More
• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., and ANIP Acquisition Co., d/b/a ANI Pharmaceuticals Inc., of Baudette, Minn., said each firm will hold a special meeting of stockholders June 19 to vote on certain matters in connection with the proposed merger of a subsidiary of BioSante into ANI. Read More
• Eisai Inc., of Woodcliff Lake, N.J., said antiepileptic drug Fycompa (perampanel) showed a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy, according to two new analyses of early clinical experience. Read More
• Argos Therapeutics Inc., of Durham, N.C., disclosed the publication of findings on its RNA amplification process. The study confirmed that the company's improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response. Read More
• Adaptive Biotechnologies, of Seattle, entered a collaboration with Bristol-Myers Squibb Co., of New York, for the discovery of immunological biomarkers in oncology. Read More
